PUBLICATIONS || CODE
wdt_ID | # | Title | Authors | Journal | Date | Photo | Photo Text |
---|---|---|---|---|---|---|---|
1 | 63 | Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting |
R. Evans, G.M. Thurber |
Scientific Reports | 2022 | ![]() |
|
2 | 62 | Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics |
S. Dong, I. Nessler, A. Kopp, B. Rubahamya, G.M. Thurber |
Frontiers in Pharmacology | 2022 | ![]() |
|
4 | 60 | Menezes, B., J.L. Linderman, G.M. Thurber |
Drug Metabolism and Disposition | 2021 | ![]() |
||
5 | 59 | Key metrics to expanding the pipeline of successful antibody-drug conjugates |
Nessler, I., B. Menezes, G.M. Thurber |
Trends in Pharmacological Sciences (TIPS) | 2021 | ![]() |
|
6 | 58 | Reply: From mice to men: the exocrine pancreas does not matter for human GLP-1 receptor imagin |
G.M. Thurber |
Journal of Nuclear Medicine (JNM) | 2021 | ||
7 | 57 | Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping |
Khera, E., C. Cilliers, M.D. Smith, M.L. Gana, K.C. Lai, T.A. Keating, A. Kopp, I. Nessler, A.O. Abu-Yousif, G.M. Thurber |
Neoplasia | 2021 | ![]() |
|
8 | 56 | Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody Drug Conjugates to Increase In Vivo Efficacy |
Ponte, J., L. Lanieri, E. Khera, R. Laleau, O. Ab, C. Espelin, N. Kohli, B. Matin, Y. Setiady, M.L. Miller, T.A. Keating, R. Chari, J. Pinkas, R. Gregory, G.M. Thurber |
Molecular Cancer Therapeutics (MCT) | 2020 | ![]() |
|
9 | 55 | Lu, G., N. Nishio, N. van den Berg, B. Martin, S. Fakurnejad, S. van Keulen, A. Dimitrios Colevas, G.M. Thurber, and E. Rosenthal |
Nature Communications | 2020 | ![]() |
||
35 | 54 | Optoacoustic imaging of GLP-1 Receptor with near-infared exendin-4 analog |
Robers, S., E. Khera, C. Choi, T. Navaratna, J. Grimm, G.M. Thurber, and T. Reiner |
Journal of Nuclear Medicine (JNM) | 2020 | ![]() |
|
36 | 53 | Nessler, I., C. Cilliers, and G.M. Thurber |
Pharmaceutics | 2020 | ![]() |
||
37 | 52 | Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Impro |
Nessler, I., E. Khera, S. Vance, A. Kopp, Q. Qiu, T.A. Keating, A. O. Abu Yousif. T. Sandal, J. Legg, L. Thompson, N. Goodwin, and G.M. Thurber |
Cancer Research | 2020 | ![]() |
|
38 | 51 | Directed Evolution Using Stabilized Bacterial Peptide Display |
Navaratna, T., L. Atangcho, M. Mahajan, V. Subramanian, M. Case, A. Min, D. Tresnak, and G.M. Thurber |
Journal of American Chemical Society | 2019 | ![]() |
|
39 | 50 | Severing Ties: Quantifying the Payload Release from Antibody Drug Conjugates |
Kopp, A. and G.M. Thurber |
Cell Chemical Biology | 2019 | ![]() |
|
41 | 48 | Menezes, B.*, C. Cilliers*, T. Wessler, G.M. Thurber, and J. Linderman |
American Association of Pharmaceutical Scientists (AAPS) | 2019 | ![]() |
||
42 | 49 | Pharmacokinetic Considerations to Maximize an ADC’s Therapeutic Index |
Thurber, G.M. |
Antibody-Drug Conjugates | 2019 | ![]() |
|
43 | 47 | Singh, A., L. Guo, A. Verma, G.Wong, G.M. Thurber, and D. Shah |
American Association of Pharmaceutical Scientists (AAPS) | 2019 | ![]() |
||
44 | 46 | Khera, E., L. Zhang, S. Roberts, I. Nessler, D. Sandoval, T. Reiner, and G.M. Thurber. |
Journal of Nuclear Medicine (JNM) | 2019 | ![]() |
||
45 | 45 | Thurber, G.M. and R. Evans |
SPIE | 2019 | |||
46 | 44 | Bhatnagar, S.*, E. Khera*, J. Liao, V. Eniola, Y. Hu, D.E. Smith, and G.M. Thurber |
Scientific Reports | 2019 | ![]() |
||
48 | 43 | Atangcho, L., T. Navaratna, and G.M. Thurber |
Trends in Biochemical Sciences | 2019 | ![]() |
||
49 | 42 | Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-gen |
Khera, E., and G.M. Thurber |
Biodrugs | 2018 | ||
50 | 41 | Bartelink, I., E. Jones, S. Shahidi-Latham, E. P. Rong, Y. Zheng, P. Vicini, L. vant Veer, D. Wolf, A. Iagaru, D. Kroetz, B. Prideaux, C. Cilliers, G. Thurber, Z. Wimana, and G. Gebhart |
Clinical Pharmacology & Therapeutics | 2018 | ![]() |
||
51 | 40 | Cilliers, C., and G.M. Thurber |
Journal of Nuclear Medicine (JNM) | 2018 | |||
52 | 39 | Nessler, I., E. Khera,and G.M. Thurber |
Oncoscience | 2018 | |||
53 | 38 | Oral administration and detection of a near-infrared molecular imaging agent in an orthotopic mous |
Bhatnagar, S., K. Dhingra Verma, Y. Hu, E. Khera, A. Priluck, D. Smith, and G.M. Thurber |
Molecular Pharmaceutics | 2018 | ||
54 | 37 | Cilliers, C., B. Menezes, I. Nessler, J. Linderman, and G.M. Thurber |
Cancer Research | 2018 | ![]() |
||
55 | 36 | Computational transport analysis of antibody-drug conjugate bystander effects and payload t |
Khera*, E., C. Cilliers*, S. Bhatnagar, and G.M Thurber |
Molecular Systems Design & Engineering | 2018 | ||
56 | 35 | Ocular toxicity profile of ST-162 and ST-168 as novel bifunctional MEK/PI3K inhibitors |
Smith, A., M. Pawar, M.E. Van Dort, S. Galbán, A.R. Welton, G.M. Thurber, B.D. Ross, and C.G. Besirli |
Ocular Pharmacology and Therapeutics | 2018 | ||
57 | 34 | Structure-guided design and initial studies of a bifunctional MEK/PI3K inhibitor (ST-168) |
Van Dort, M.E., S. Galbán, C.A. Nino, H. Hong, A.A. Apfelbaum, G.D. Luker, G.M. Thurber, L. Atangcho, C.G. Besirli, and B.D. Ross |
ACS Medicinal Chemistry Letters | 2018 | ||
58 | 33 | Tracking antibody distribution with near infrared fluorescent dyes: impact of dye structure and de |
Cilliers, C., I. Nessler, N. Christodolu, and G.M. Thurber |
Molecular Pharmaceutics | 2017 | ||
59 | 32 | Zhang, L., and G.M. Thurber |
Imaging and Metabolism | 2018 | |||
60 | 31 | A helix-stabilizing linker improves subcutaneous bioavailability of a helical peptide independent of |
Zhang, L., T. Navaratna, and G.M. Thurber |
Bioconjugate Chemistry | 2016 | ||
61 | 30 | Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to w |
Cilliers, C., H. Guo, J. Liao, N. Christodolu, and G.M. Thurber. |
American Association of Pharmaceutical Scientists (AAPS) | 2016 | ||
62 | 29 | Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design |
Zhang, L.*, S. Bhatnagar*, E. Deschenes, and G.M. Thurber |
Scientific Reports | 2016 | ||
63 | 28 | Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging</ |
Zhang, L. and G.M. Thurber |
Molecular Imaging and Biology | 2016 | ||
64 | 27 | Tumor Effect-Site Pharmacokinetics: Mechanisms and impact on efficacy |
G.M. Thurber |
ADME and Translational PK/PD of Therapeutic Proteins: Applications in Drug Discovery and Development | 2015 | ||
65 | 26 | Advances in measuring single-cell pharmacokinetics and pharmacology in vivo</ |
Vinegoni, C., J.M. Dubach, G.M. Thurber, M.A. Miller, R. Mazitschek, and R. Weissleder |
Drug Discovery Today | 2015 | ||
66 | 25 | Residualization rates of near infrared dyes for the rational design of molecular imaging agents</ |
Cilliers, C., J. Liao, L. Atangcho, and G.M. Thurber |
Molecular Imaging and Biology | 2015 | ||
67 | 24 | Zhang, L., T. Navaratna, J. Liao, and G.M. Thurber |
Bioconjugate Chemistry | 2015 | |||
68 | 23 | Population dynamics of islet-infiltrating cells in autoimmune diabetes |
Magnuson, A.M, G.M. Thurber, R.H Kohler, R. Weissleder, D. Mathis, and C. Benoist |
Proc Natl Acad Sci USA | 2015 | ||
69 | 22 | A systems pharmacology approach towards the design of inhaled formulations of rifampicin and isonia |
Cilfone, N., E. Pienaar, G.M. Thurber, D. Kirschner, and J. Linderman |
CPT Pharmacometrics and Systems Pharmacology | 2015 | ||
70 | 21 | Multichannel imaging to quantify four classes of pharmacokinetic distribution |
Bhatnagar, S., E. Deschenes, J. Liao, C. Cilliers, and G.M. Thurber |
Pharmaceutical Sciences | 2014 | ||
71 | 20 | Effect of small molecule modification on single cell pharmacokinetics of PARP inhibitors |
Thurber, G.M., T. Reiner, K.S. Yang, R.H. Kohler, and R. Weissleder |
Molecular Cancer Therapeutics (MCT) | 2014 | ||
72 | 19 | Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo |
Thurber, G.M., K.S. Yang, T. Reiner, R.H. Kohler, P. Sorger, T. Mitchison, and R. Weissleder |
Nature Communications | 2013 | ||
73 | 18 | A mechanistic compartmental model for antibody uptake in tumors |
Thurber, G.M. and K.D. Wittrup |
Theoretical Biology | 2012 | ||
74 | 17 | Noise suppressed, multifocus image fusion for enhanced intraoperative navigation |
Feruglio, P.F., C. Vinegoni, L. Fexon, G.M. Thurber, A. Sbarbati, R. Weissleder |
Biophotonics | 2012 | ||
75 | 16 | Efficient 18F-Labeling of Synthetic Exendin-4 Analogues for Imaging Beta Cells |
Keliher, E.J., T. Reiner, G.M. Thurber, R. Upadhyay, R. Weissleder |
Chemistry Open | 2012 | ||
76 | 15 | Reactive Polymer Enables Efficient In Vivo Bioorthogonal Chemistry |
Devaraj NK*, G.M. Thurber*, E.J. Keliher, B. Marinelli, R. Weissleder |
Proc Natl Acad Sci USA | 2012 | ||
77 | 14 | Practical Theroretic Guidance for the Design of Tumor Targeting Agents |
Wittrup K.D., G.M. Thurber, M.M. Schmidt, J.J. Rhoden |
Methods in Enzymology | 2012 | ||
78 | 13 | Thurber, G.M.*, R. Weissleder* |
PLoS ONE | 2011 | |||
79 | 12 | Accurate Measurement of Beta Cell Mass Using a Second-Generation Fluorescent Exendin-4 Analog |
Reiner T., G.M. Thurber, J. Gaglia, et al. |
Proc Natl Acad Sci USA | 2011 | ||
80 | 11 | Targeted Radionuclide Therapy, Chapter 12 |
Thurber G.M. |
Targeted Radionuclide Therapy, Chapter 12 | 2011 | ||
81 | 10 | Quantitaing Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels |
Thurber, G.M. and R. Weissleder |
Molecular Imaging and Biology | 2011 | ||
82 | 9 | Detection Limits of Intraoperative Near Infared Imaging for Tumor Resection |
Thurber, G.M., J.L. Figueiredo, R. Weissleder |
Surgical Oncology | 2010 | ||
83 | 8 | Thurber, G.M., J.L. Figueiredo and R. Weissleder |
PLoS ONE | 2009 | |||
84 | 7 | Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors</p |
Nahrendorf, M., P. Waterman, G.M. Thurber, K. Groves, M. Rajopadhye, P. Panizzi, B Marinelli, E. Aikawa, M.J. Pittet, F.K. Swirski, and R. Weissleder |
Arteriosclerosis, Thrombosis, and Vascular Biology | 2009 | ||
85 | 6 | Devaraj, N.K., E.J. Keliher, G.M. Thurber, M. Nahrendorf, and R. Weissleder |
Bioconjugate Chemistry | 2009 | |||
86 | 5 | Schmidt, M.M., G.M. Thurber, and K.D. Wittrup |
Cancer Immunology and Immunotherapy | 2008 | |||
87 | 4 | Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance |
Thurber, G.M., M.M. Schmidt, and K.D. Wittrup |
Advanced Drug Delivery Reviews | 2008 | ||
88 | 3 | Thurber, G.M. and K.D. Wittrup |
Cancer Research | 2008 | |||
89 | 2 | Thurber, G.M., M.M. Schmidt, and K.D. Wittrup |
Trends in Pharmacological Sciences | 2008 | |||
90 | 1 | Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases |
Thurber, G.M., S.C. Zajic, and K.D. Wittrup |
Journal of Nuclear Medicine (JNM) | 2007 | ||
91 | 64 | Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates |
E. Khera, S. Dong, H. Huang, L. de Bever, F. van Delft, G. Thurber |
Molecular Cancer Therapeutics | 2022 | ![]() |
|
92 | 65 | B. Menezes, E. Khera, M. Calopiz, M. Smith, M. Ganno, C. Cilliers, A. Abu-Yousif, J. Linderman, G. Thurber |
American Association of Pharmaceutical Scientists (AAPS) | 2022 | ![]() |
||
93 | 66 | A. Kopp, S. Hofsess, T. M. Cardillo, S. V. Govindan, J. Donnell, G. Thurber |
Molecular Cancer Therapeutics | 2022 | ![]() |
||
95 | 67 | Rapid Evaluation of Staple Placement in Stabilized ⍺ Helices Using Bacterial Surface Display |
M. Case, T. Navaratna, J. Vinh. G. M. Thurber |
ACS Chemical Biology | 2023 | ![]() |
|
96 | 69 | E. Khera, J. Kim, A. Stein, M. Ratanapanichkich, G. M. Thurber |
Journal of Pharmacology and Experimental Therapeutics (JPET) | 2023 | ![]() |
||
97 | 70 | Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembry |
I. Nessler, B. Rubahamya, A. Kopp, S. Hofsess, T. M. Cardillo, N. Sathyanarayan, J. Donnell, S. V. Govindan, G. M. Thurber |
Molecular Cancer Therapeutics | 2023 | ![]() |
|
98 | 68 | L. de Bever, S. Popal, J. van Schaik, B. Rubahamya, F. van Delft, G. M. Thurber, S. van Berkel |
Bioconjugate Chemistry | 2023 | ![]() |
||
99 | 71 | Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents |
A. Kopp, J. Kwon, C. Johnston, S. Vance, J. Legg, L. Galson-Holt, G. M. Thurber |
Neoplasia (in press) | 2023 | ![]() |
|
100 | 72 | M. Case, M. Smith, J. Vinh, G. M. Thurber |
Proceedings of the National Academy of Sciences (PNAS) | 2024 | ![]() |
||
101 | 73 | M. Calopiz, J. J. Linderman, G. M. Thurber |
Pharmaceutical Research | 2024 | ![]() |
||
102 | 74 | A. Kopp, J. Guan, C. Johnston, S. Vance, J. Legg, L. Galson-Holt, G. M. Thurber |
American Association for Pharmaceutical Scientists (AAPS) | 2024 | ![]() |
||
103 | 75 | Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data |
B. Rubahamya, S. Dong, G. M. Thurber |
Science Advances | 2024 | ![]() |
|
104 | 76 | Maximizing activity and selectivity of antibody-mediated effector functions using antibody mixtures |
T. Wang, A. Desai, G. M. Thurber, P. M. Tessier |
mAbs | 2025 | ![]() |